Pharmaron Beijing Co Ltd
HKEX:3759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
HKEX:3759
Watchlist
Price: 20.58 HKD -2% Market Closed
Market Cap: HK$58.9B

EV/OCF

16.7
Current
11%
Cheaper
vs 3-y average of 18.7

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
16.7
=
Enterprise Value
HK$54.4B
/
Operating Cash Flow
¥3.2B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
16.7
=
Enterprise Value
HK$54.4B
/
Operating Cash Flow
¥3.2B

Valuation Scenarios

Pharmaron Beijing Co Ltd is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (18.7), the stock would be worth HK$23.14 (12% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+28%
Average Upside
22%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 16.7 HK$20.58
0%
3-Year Average 18.7 HK$23.14
+12%
5-Year Average 21.4 HK$26.44
+28%
Industry Average 20.1 HK$24.79
+20%
Country Average 20.8 HK$25.72
+25%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CN
Pharmaron Beijing Co Ltd
HKEX:3759
52.7B HKD 16.7 31.7
US
PerkinElmer Inc
LSE:0KHE
1T USD 1 774.1 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
174.6B USD 25.5 25.5
US
Danaher Corp
NYSE:DHR
125.4B USD 21.3 34
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 36.2 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
298.9B CNY 15.4 15.6
CH
Lonza Group AG
SIX:LONN
34.3B CHF 31 -118.2
US
Agilent Technologies Inc
NYSE:A
32.7B USD 24.5 25.3
US
Waters Corp
NYSE:WAT
30.4B USD 47.1 47.3
US
IQVIA Holdings Inc
NYSE:IQV
27.5B USD 14.8 20.3
US
Mettler-Toledo International Inc
NYSE:MTD
26.1B USD 29.4 30

Market Distribution

In line with most companies in China
Percentile
48th
Based on 6 190 companies
48th percentile
19.6
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

Pharmaron Beijing Co Ltd
Glance View

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Intrinsic Value
28.82 HKD
Undervaluation 29%
Intrinsic Value
Price HK$20.58
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett